ABSTRACT
Objective To demonstrate the effect on platelet aggregation rate (PAR) and clinical outcomes of tirofiban in patients undergoing emergency percutaneous coronary intervention (PCI) and to evaluate its safety. Methods Thirty patients presenting with STEMI and had received emergency PCI were enrolled into the tirofiban group. By means of matching, another 30 patients who received elective PCI during the same period from September 2005 to March 2006 were enrolled as the control in the 2nd Xiangya Hospital of Central South University. Patients in the tirofiban group received tirofiban infused at 10 ?g/kg within 3 minutes as bolus 10-30 minutes pre-operation followed by infusion at 0.15 ?g/(kg?min) for 36 hours. The control group received the same dosage of placebo. All patients received intravenous heparin and oral ADP receptor antagonist and aspirin. PAR, incidence of 7 and 30 days composite end point events (death, persistent myocardial ischemic, reinfarction and target vessel revascularization) and bleeding complications were observed in both groups. Results Compared with the control group, the tirofiban group showed a decrease in PAR (19?8)% vs (54?7)%, P